SciBase CEO shares his knowledge and perspectives;
“SciBase has advanced its positions significantly and laid the foundation for continued growth”
SciBase CEO Pia Renaudin reflects on the most important moments of 2024
“We continue our momentum across all markets”
SciBase CEO Pia Renaudin shares her view on the latest Q2 Report
Letter from the CEO
SciBase newly appointed CEO, Pia Renaudin share here thoughts on SciBase path forward.
Letter from the Board
SciBase´s Chairman of the Board, Tord Lendau, on the company’s focus and strategy as SciBase paves the way for the future.
CEO Letter 10 – December 2022
As the end of 2022 approaches, Simon Grant, CEO of SciBase, summarizes the highlights that made this year an extremely eventful year.
CEO Letter 9 – January 2022
On MDR, NMSC and US Strategy.
CEO Letter 8 – September 2020
Nevisense Go & MDR.
CEO Letter 7 – July 2020
Progress and Covid-19.
CEO Letter 6 – May 2020
US progress and Nevisense Go.
CEO Letter 5 – April 2019
Nevisense 3.0 and Skin Barrier application.
CEO-letter 4 – November 2017
Updated strategy and securing our long-term capital needs.
CEO-letter 3 – April 2017
Future trends and technologies.
CEO-letter 2 – January 2017
Nevisense View – a new product with great potential.
CEO-letter 1 – December 2016
Teledermoscopy – good for increased awareness and access but is it good enough as a diagnostic method?